Advancing the Future of Live Biotherapeutics: Faecalibacterium duncaniae Research Service
The human microbiome is no longer viewed as a passive collection of passengers; it is recognized as a sophisticated metabolic organ that dictates the boundaries of health and disease. Among the diverse taxa inhabiting the human gut, the genus Faecalibacterium has emerged as a cornerstone of intestinal homeostasis. Specifically, Faecalibacterium duncaniae-formerly categorized within the broader F. prausnitzii phylogroups-has become a focal point for next-generation probiotic (NGP) development and Live Biotherapeutic Products (LBPs). As a premier Contract Research Organization (CRO) specializing in preclinical microbiome solutions, Creative Biolabs is dedicated to providing the foundational data, specialized assays, and high-quality microbial products necessary to transition F. duncaniae from a laboratory curiosity to a clinical reality. Our mission is to bridge the gap between complex microbial ecology and rigorous pharmaceutical standards, ensuring that your therapeutic candidates are backed by robust, reproducible, and translatable evidence.
Overview: The Significance of Faecalibacterium duncaniae
Faecalibacterium duncaniae is an anaerobic, Gram-positive bacterium that belongs to the Ruminococcaceae family. While Faecalibacterium prausnitzii was long considered a single species, recent genomic and phenotypic reclassifications have identified F. duncaniae as a distinct and vital member of the human colonic microbiota. It is often cited as one of the most abundant bacteria in the healthy adult gut, typically comprising 5% to 15% of the total bacterial population.
The primary biological significance of F. duncaniae lies in its role as a "butyrate factory." Through the fermentation of dietary fibers, it produces high concentrations of butyrate, a short-chain fatty acid (SCFA) that serves as the primary energy source for colonocytes. Beyond energy production, butyrate acts as a signaling molecule that maintains the integrity of the intestinal barrier and modulates the mucosal immune system. Research has consistently shown that a depletion of F. duncaniae is a hallmark of "dysbiosis" in various systemic and localized inflammatory conditions. Unlike traditional probiotics like Lactobacillus or Bifidobacterium, F. duncaniae is an extremely oxygen-sensitive (EOS) bacterium, making it significantly harder to isolate, culture, and stabilize. This complexity is exactly why specialized preclinical services are required to unlock its therapeutic potential.
Comprehensive Preclinical Research Services
Our CRO provides an end-to-end service platform specifically tailored for Faecalibacterium duncaniae and related Live Biotherapeutics. We understand that working with EOS (Extremely Oxygen-Sensitive) strains requires specialized infrastructure and expertise.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Faecalibacterium prausnitzii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Application of F. duncaniae in Disease Treatment
The therapeutic applications of F. duncaniae are vast, primarily centered on its potent anti-inflammatory properties and its ability to restore gut barrier function. Researchers are currently exploring its efficacy across several major disease categories:
Crohn's Disease and Ulcerative Colitis are characterized by a marked reduction in Faecalibacterium abundance. F. duncaniae exerts a protective effect by secreting anti-inflammatory peptides, such as Microbial Anti-inflammatory Molecule (MAM). This protein inhibits the NF-κB pathway, thereby reducing the production of pro-inflammatory cytokines like IL-12 and TNF-α while promoting the secretion of the anti-inflammatory cytokine IL-10.
Emerging evidence suggests that F. duncaniae plays a role in metabolic health. By strengthening the gut barrier, it prevents "leaky gut" syndrome—the translocation of lipopolysaccharides (LPS) into the bloodstream. This reduction in metabolic endotoxemia helps mitigate insulin resistance, obesity-related inflammation, and Type 2 Diabetes.
3. Immuno-Oncology
The microbiome is a critical determinant of a patient's response to Immune Checkpoint Inhibitors (ICIs). High levels of Faecalibacterium in the gut have been correlated with improved progression-free survival in melanoma patients treated with anti-PD-1 therapy. F. duncaniae appears to modulate systemic immunity, enhancing the recruitment of T-cells to the tumor microenvironment.
4. Gut-Brain Axis
The butyrate produced by F. duncaniae can cross the blood-brain barrier or influence the vagus nerve. Preliminary studies are investigating its impact on neuropsychiatric conditions such as major depressive disorder and anxiety, where gut inflammation is increasingly recognized as a contributing factor.
Our Advantages: Why Partner With Us?
Specialized Anaerobic Expertise
Our laboratories are equipped with state-of-the-art anaerobic workstations that maintain oxygen levels below 5 ppm at all times, ensuring the viability of even the most sensitive F. duncaniae isolates.
Multi-Omics Integration
We don't just provide raw data. We integrate metagenomics, transcriptomics, and metabolomics to provide a holistic view of how your LBP candidate interacts with the host.
Regulatory Alignment
Our preclinical protocols are designed with IND (Investigational New Drug) applications in mind, following the latest guidelines for Live Biotherapeutic Products.
Proven Track Record
As a specialized CRO, we have successfully supported dozens of biotech companies in moving their microbiome candidates from the "hit" stage to "lead" optimization.
The transition of Faecalibacterium duncaniae from a lab curiosity to a clinical reality represents a milestone in gastroenterology. We believe that restoring this "missing microbe" is not just a treatment but a fundamental correction of the modern human ecosystem. By partnering with us, you are not just outsourcing a study; you are collaborating with experts dedicated to proving that the gut microbiome is the most powerful pharmacy ever discovered.
Why is F. duncaniae so much harder to study than Lactobacillus?
Unlike common probiotics, F. duncaniae is an obligate anaerobe that dies within minutes of exposure to ambient air. This requires specialized handling, oxygen-free reagents, and sophisticated equipment throughout the entire research process.
Can F. duncaniae be used as a traditional dietary supplement?
Currently, due to its regulatory status and manufacturing difficulty, it is primarily being developed as a "Live Biotherapeutic Product" (LBP) under pharmaceutical regulations rather than a standard food-grade probiotic.
How do you ensure the stability of the strain during transport?
We use specialized cold-chain logistics and anaerobic transport media. For lyophilized products, we utilize moisture-resistant, vacuum-sealed packaging to maintain maximum viability.
Do you provide genomic analysis for IP protection?
Yes, we provide comprehensive genomic fingerprinting and comparative genomics to help you define and protect your unique therapeutic strain.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
